| . | Total n = 52 . | Surgery n = 46 . | No surgery n = 6 . | P value . |
|---|---|---|---|---|
| Age (years) | 61 (53–68) | 61 (54–68) | 55 (42–70) | 0.475 |
| Male sex, n (%) | 29 (56) | 25 (54) | 4 (67) | 0.568 |
| Chief complaint, n (%) | 0.249 | |||
| Pain | 24 (46) | 19 (41) | 5 (83) | |
| Palpable mass | 14 (27) | 14 (30) | 1 (17) | |
| Incidental (from imaging) | 8 (17) | 8 (17) | 0 (0) | |
| Unknown | 6 (12) | 6 (13) | 0 (0) | |
| Tumour size (cm) | 15 (10–23) | 15 (10–23) | 15 (9–23) | 0.891 |
| Tumour laterality (right side), n (%) | 28 (54) | 26 (56) | 2 (33) | 0.397 |
| Examination before treatment, n (%) | ||||
| Biopsy, n (%) | 21 (40) | 16 (35) | 5 (83) | 0.034 |
| CT, n (%) | 40 (77) | 34 (74) | 6 (100) | 0.316 |
| MRI, n (%) | 24 (46) | 20 (43) | 4 (67) | 0.397 |
| PET, n (%) | 13 (25) | 11 (24) | 2 (33) | 0.632 |
| Diagnosis of liposarcoma before treatment, n (%) | 40 (77) | 35 (76) | 5 (83) | 0.692 |
| Multifocal disease, n (%) | 15 (29) | 14 (30) | 1 (17) | 0.659 |
| Lymph node metastasis, n (%) | 4 (8) | 2 (4) | 2 (33) | 0.061 |
| Distant metastasis, n (%) | 3 (6) | 0 (0) | 3 (50) | 0.001 |
| Pathological subtype, n (%) | 0.497 | |||
| Well-differentiated | 22 (42) | 21 (46) | 1 (17) | |
| Dedifferentiated | 25 (48) | 21 (46) | 4 (67) | |
| Myxoid | 4 (8) | 3 (7) | 1 (17) | |
| Pleomorphic | 1 (2) | 1 (2) | 0 (0) |
| . | Total n = 52 . | Surgery n = 46 . | No surgery n = 6 . | P value . |
|---|---|---|---|---|
| Age (years) | 61 (53–68) | 61 (54–68) | 55 (42–70) | 0.475 |
| Male sex, n (%) | 29 (56) | 25 (54) | 4 (67) | 0.568 |
| Chief complaint, n (%) | 0.249 | |||
| Pain | 24 (46) | 19 (41) | 5 (83) | |
| Palpable mass | 14 (27) | 14 (30) | 1 (17) | |
| Incidental (from imaging) | 8 (17) | 8 (17) | 0 (0) | |
| Unknown | 6 (12) | 6 (13) | 0 (0) | |
| Tumour size (cm) | 15 (10–23) | 15 (10–23) | 15 (9–23) | 0.891 |
| Tumour laterality (right side), n (%) | 28 (54) | 26 (56) | 2 (33) | 0.397 |
| Examination before treatment, n (%) | ||||
| Biopsy, n (%) | 21 (40) | 16 (35) | 5 (83) | 0.034 |
| CT, n (%) | 40 (77) | 34 (74) | 6 (100) | 0.316 |
| MRI, n (%) | 24 (46) | 20 (43) | 4 (67) | 0.397 |
| PET, n (%) | 13 (25) | 11 (24) | 2 (33) | 0.632 |
| Diagnosis of liposarcoma before treatment, n (%) | 40 (77) | 35 (76) | 5 (83) | 0.692 |
| Multifocal disease, n (%) | 15 (29) | 14 (30) | 1 (17) | 0.659 |
| Lymph node metastasis, n (%) | 4 (8) | 2 (4) | 2 (33) | 0.061 |
| Distant metastasis, n (%) | 3 (6) | 0 (0) | 3 (50) | 0.001 |
| Pathological subtype, n (%) | 0.497 | |||
| Well-differentiated | 22 (42) | 21 (46) | 1 (17) | |
| Dedifferentiated | 25 (48) | 21 (46) | 4 (67) | |
| Myxoid | 4 (8) | 3 (7) | 1 (17) | |
| Pleomorphic | 1 (2) | 1 (2) | 0 (0) |
Data are presented as medians with IQRs or numbers with percentages (%).
RLS, retroperitoneal liposarcoma; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; IQR, interquartile range.
| . | Total n = 52 . | Surgery n = 46 . | No surgery n = 6 . | P value . |
|---|---|---|---|---|
| Age (years) | 61 (53–68) | 61 (54–68) | 55 (42–70) | 0.475 |
| Male sex, n (%) | 29 (56) | 25 (54) | 4 (67) | 0.568 |
| Chief complaint, n (%) | 0.249 | |||
| Pain | 24 (46) | 19 (41) | 5 (83) | |
| Palpable mass | 14 (27) | 14 (30) | 1 (17) | |
| Incidental (from imaging) | 8 (17) | 8 (17) | 0 (0) | |
| Unknown | 6 (12) | 6 (13) | 0 (0) | |
| Tumour size (cm) | 15 (10–23) | 15 (10–23) | 15 (9–23) | 0.891 |
| Tumour laterality (right side), n (%) | 28 (54) | 26 (56) | 2 (33) | 0.397 |
| Examination before treatment, n (%) | ||||
| Biopsy, n (%) | 21 (40) | 16 (35) | 5 (83) | 0.034 |
| CT, n (%) | 40 (77) | 34 (74) | 6 (100) | 0.316 |
| MRI, n (%) | 24 (46) | 20 (43) | 4 (67) | 0.397 |
| PET, n (%) | 13 (25) | 11 (24) | 2 (33) | 0.632 |
| Diagnosis of liposarcoma before treatment, n (%) | 40 (77) | 35 (76) | 5 (83) | 0.692 |
| Multifocal disease, n (%) | 15 (29) | 14 (30) | 1 (17) | 0.659 |
| Lymph node metastasis, n (%) | 4 (8) | 2 (4) | 2 (33) | 0.061 |
| Distant metastasis, n (%) | 3 (6) | 0 (0) | 3 (50) | 0.001 |
| Pathological subtype, n (%) | 0.497 | |||
| Well-differentiated | 22 (42) | 21 (46) | 1 (17) | |
| Dedifferentiated | 25 (48) | 21 (46) | 4 (67) | |
| Myxoid | 4 (8) | 3 (7) | 1 (17) | |
| Pleomorphic | 1 (2) | 1 (2) | 0 (0) |
| . | Total n = 52 . | Surgery n = 46 . | No surgery n = 6 . | P value . |
|---|---|---|---|---|
| Age (years) | 61 (53–68) | 61 (54–68) | 55 (42–70) | 0.475 |
| Male sex, n (%) | 29 (56) | 25 (54) | 4 (67) | 0.568 |
| Chief complaint, n (%) | 0.249 | |||
| Pain | 24 (46) | 19 (41) | 5 (83) | |
| Palpable mass | 14 (27) | 14 (30) | 1 (17) | |
| Incidental (from imaging) | 8 (17) | 8 (17) | 0 (0) | |
| Unknown | 6 (12) | 6 (13) | 0 (0) | |
| Tumour size (cm) | 15 (10–23) | 15 (10–23) | 15 (9–23) | 0.891 |
| Tumour laterality (right side), n (%) | 28 (54) | 26 (56) | 2 (33) | 0.397 |
| Examination before treatment, n (%) | ||||
| Biopsy, n (%) | 21 (40) | 16 (35) | 5 (83) | 0.034 |
| CT, n (%) | 40 (77) | 34 (74) | 6 (100) | 0.316 |
| MRI, n (%) | 24 (46) | 20 (43) | 4 (67) | 0.397 |
| PET, n (%) | 13 (25) | 11 (24) | 2 (33) | 0.632 |
| Diagnosis of liposarcoma before treatment, n (%) | 40 (77) | 35 (76) | 5 (83) | 0.692 |
| Multifocal disease, n (%) | 15 (29) | 14 (30) | 1 (17) | 0.659 |
| Lymph node metastasis, n (%) | 4 (8) | 2 (4) | 2 (33) | 0.061 |
| Distant metastasis, n (%) | 3 (6) | 0 (0) | 3 (50) | 0.001 |
| Pathological subtype, n (%) | 0.497 | |||
| Well-differentiated | 22 (42) | 21 (46) | 1 (17) | |
| Dedifferentiated | 25 (48) | 21 (46) | 4 (67) | |
| Myxoid | 4 (8) | 3 (7) | 1 (17) | |
| Pleomorphic | 1 (2) | 1 (2) | 0 (0) |
Data are presented as medians with IQRs or numbers with percentages (%).
RLS, retroperitoneal liposarcoma; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; IQR, interquartile range.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
